Dimethylarginine Dimethylaminohydrolase-1 Is the Critical Enzyme for Degrading the Cardiovascular Risk Factor Asymmetrical Dimethylarginine | Zendy

Xinli Hu | Zendy; Dorothee Atzler | Zendy; Xin Xu | Zendy; Ping Zhang | Zendy; Haipeng Guo | Zendy; Zhongbing Lu | Zendy; John Fassett | Zendy; Edzard Schwedhelm | Zendy; Rainer H. Böger | Zendy; Robert J. Bache | Zendy; Yingjie Chen | Zendy

Open Access

Dimethylarginine Dimethylaminohydrolase-1 Is the Critical Enzyme for Degrading the Cardiovascular Risk Factor Asymmetrical Dimethylarginine

Author(s) -

Xinli Hu,

Dorothee Atzler,

Xin Xu,

Ping Zhang,

Haipeng Guo,

Zhongbing Lu,

John Fassett,

Edzard Schwedhelm,

Rainer H. Böger,

Robert J. Bache,

Yingjie Chen

Publication year - 2011

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.110.222638

Subject(s) - asymmetric dimethylarginine , arginine , nitric oxide , nitric oxide synthase , medicine , endocrinology , chemistry , enzyme , biochemistry , amino acid

The objective of this study was to identify the role of dimethylarginine dimethylaminohydrolase-1 (DDAH1) in degrading the endogenous nitric oxide synthase inhibitors asymmetrical dimethylarginine (ADMA) and N(g)-monomethyl-L-arginine (L-NMMA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research